February 2026 CLL Bloodline
January 30, 2026
February 2026 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
February 2026 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
MRD-guided ibrutinib-venetoclax significantly improved outcomes for previously untreated patients with CLL compared with ibrutinib or chemoimmunotherapy.
BeiGene and CLL Society partnered on Test Before Treat, educating healthcare providers and CLL / SLL patients about the importance of biomarker testing.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
I found out last week that I am not only in a complete remission, but also there was no measurable CLL in my peripheral blood done by flow cytometry, down to 1 in 10,000 cells
A newly published paper in JAMA Oncology found that among cancer patients with suspected ibrutinib-related cardiotoxic effects, the presence of heart muscle injury and scarring is high, and this is associated with an increased risk of developing future cardiovascular adverse events.
Dr. Ed Ratner’s Review of For Blood and Money by Nathan Vardi that chronicles the development of two blockbuster drugs
Over the course of a year of monthly meetings, the CLL Bloodline will teach the BASICS needed to understand CLL, bring news, help with the acronyms and new vocabulary, and offer